Financial Performance - Revenue for the six months ended December 31, 2023, was HKD 190,330,000, a decrease of 53% compared to HKD 405,080,000 for the same period in 2022[2] - Gross profit for the same period was HKD 16,795,000, down 37% from HKD 26,691,000 year-on-year[2] - The net loss for the six months ended December 31, 2023, was HKD 4,030,000, an improvement from a net loss of HKD 5,308,000 in the previous year[3] - Basic and diluted loss per share was HKD 3.93, compared to HKD 4.57 for the same period in 2022[3] - The company reported a loss attributable to owners of approximately HKD 6,734,000 for the six months ended December 31, 2023, compared to a loss of HKD 7,831,000 for the same period in 2022, indicating a reduction in loss[37] - The company incurred a total comprehensive loss of HKD 4,030,000 for the six months ended December 31, 2023, compared to a loss of HKD 5,308,000 for the same period in 2022[22] Assets and Liabilities - Non-current assets increased to HKD 131,647,000 as of December 31, 2023, from HKD 111,059,000 as of June 30, 2023[7] - Current assets totaled HKD 133,902,000, slightly up from HKD 129,172,000 at the end of June 2023[7] - Current liabilities increased to HKD 179,488,000 from HKD 158,829,000, resulting in a negative net current liabilities of HKD 45,586,000[7] - As of December 31, 2023, the group's net current liabilities were approximately HKD 45,586,000, an increase from HKD 29,657,000 as of June 30, 2023[38] - The current ratio as of December 31, 2023, was approximately 0.79, slightly down from 0.81 as of June 30, 2023[38] - The asset-to-liability ratio (excluding cash and cash equivalents) was approximately 43.8% as of December 31, 2023, down from 53.3% as of June 30, 2023[38] Revenue Sources - Revenue from the manufacturing and sales of modified starch and other biochemical products was approximately HKD 190,330,000 for the six months ended December 31, 2023, a decrease of 53% compared to HKD 405,080,000 for the same period in 2022[17][22] - The company reported a segment profit of HKD 7,959,000 from modified starch and other biochemical products for the six months ended December 31, 2023, compared to HKD 8,067,000 for the same period in 2022[22] - The company continues to focus on the manufacturing and sales of modified starch and other biochemical products[11] Strategic Initiatives - The company plans to pursue strategic acquisitions to gain new opportunities in the Chinese market and strengthen its revenue and profit base[14] - The company is actively seeking growth projects for acquisition or investment and is in discussions with various parties regarding such opportunities[14] - The company has secured loans of approximately HKD 4,641,000 and has access to additional financing of about HKD 65,359,000 from its ultimate holding company, indicating efforts to ensure sufficient cash resources for operational needs[14][16] - The group continues to implement measures to improve its financial situation, including securing loans from the ultimate holding company and monitoring operational costs closely[39] Cost Management - Administrative expenses decreased by 10.9% to approximately HKD 9,412,000 for the six months ended December 31, 2023, down from HKD 10,566,000 in the same period of 2022[37] - The company’s cost control measures have contributed to a reduction in employee costs, impacting overall administrative expenses positively[37] - The company continues to implement measures to improve its working capital and cash flow, including close monitoring of general administrative expenses and operating costs[16] Taxation - The income tax expense for the six months ended December 31, 2023, was HKD 1,185,000, compared to HKD 1,529,000 for the same period in 2022[23] - The company has not incurred any tax liabilities in Hong Kong for the periods under review due to the absence of taxable profits[24] Dividends - The company did not recommend any interim dividend for the six months ended December 31, 2023, consistent with the previous year[27] - The company has decided not to declare an interim dividend for the six months ending December 31, 2023, consistent with the previous year[41] Compliance and Review - The board of directors has confirmed compliance with the standard code of conduct for securities transactions throughout the review period[44] - The audit committee has reviewed the unaudited interim financial results for the six months ending December 31, 2023[49]
玮俊生物科技(00660) - 2024 - 中期业绩